Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 71

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

Summary

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 10 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Cardiovascular, Genetic Disorders, Ophthalmology and Respiratory which include indications Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma, Autoimmune Disorders, Celiac Disease, Crohn's Disease (Regional Enteritis), Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Multiple Sclerosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Ventricular Septal Defect.

Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

- The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Takeda Pharmaceutical Co Ltd
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carotegrast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-5232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan
Jun 05, 2018: Analysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohn's disease patients
Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies
Feb 28, 2018: Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy
Feb 16, 2018: Entyvio (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis
Feb 07, 2018: Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Feb 06, 2018: Takeda Announces Publication of Study Utilizing State-of-the-Art Modeling to Better Understand Optimal Treatment Positioning for Patients with Ulcerative Colitis
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update
Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conferenc
Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
Oct 30, 2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting
Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update
Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Naïve Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Antisense Therapeutics Ltd, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by BioMAS Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by EA Pharma Co Ltd, H2 2018
Pipeline by Immunwork Inc, H2 2018
Pipeline by Morphic Therapeutic Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Effervescent Tablet Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 116
    Effervescent tablets are designed to break in contact with liquid such as water or juice, often causing the tablet to dissolve into a solution. In 2017, the global Effervescent Tablet market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Effervescent Tablet market based on company, product type, application and key regions. This report stud......
  • Global Rivanol Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 117
    Rivanol is for external use sterilization preservative, the gram positive bacteria and a few gram-negative bacteria have strong exterminate action, to cocci especially streptococcus antibacterial effect strong. It is used for all kinds of wounds, seepage, erosion of infectious skin disease and wound flushing. In 2017, the global Rivanol market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, ......
  • Global Pregnant Vitamin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 115
    For pregnant women, vitamin supplements are needed during pregnancy to ensure adequate nutrition for the fetus. Vitamins are essential not only for pregnant women, but also for the development of babies. In 2017, the global Pregnant Vitamin market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Pregnant Vitamin market based on company, product type, applic......
  • Global Children Calcium supplement Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 119
    Calcium is the essential building block of bones and teeth, Children Calcium Tablet can provide daily calcium volume to children. In 2017, the global Children Calcium supplement market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Children Calcium supplement market based on company, product type, application and key regions. This report st......
  • Global G-CSF and G-CSF Biosimilars Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 115
    G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation. In 2017, the global G-CSF and G-CSF Biosimilars market size was xx million US$ and is forecast to xx m......
  • Global Animal Health Products Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 112
    Animal Health Products include some products vaccines, pharmaceuticals, feed additivies and others. In 2017, the global Animal Health Products market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Animal Health Products market based on company, product type, application and key regions. This report studies the global market size of Animal H......
  • Global Human Endostatin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 114
    This report studies the global market size of Human Endostatin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Endostatin in these regions. This research report categorizes the global Human Endostatin market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, o......
  • Global Poliomyelitis Vaccine in Dragee Candy Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 113
    This report studies the global market size of Poliomyelitis Vaccine in Dragee Candy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Poliomyelitis Vaccine in Dragee Candy in these regions. This research report categorizes the global Poliomyelitis Vaccine in Dragee Candy market by players/brands, region, type and application. This report also studies the global market status, competition landsca......
  • Global Interleukin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 113
    This report studies the global market size of Interleukin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Interleukin in these regions. This research report categorizes the global Interleukin market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs